Seelos Therapeutics Total Liabilities

The latest total liabilities for SEEL is $31M as of June 2024. That compares with $59M in the prior-year period — down 48.3% year over year. Investors often review this figure alongside Seelos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SEEL's total liabilities moved from $59M to $31M — a 48.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Seelos Therapeutics's operating scale or balance-sheet position.

A total liabilities figure of $31M for SEEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SEEL's total liabilities ($31M), review year-over-year change from $59M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Seelos Therapeutics's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.